Final analysis of PROpel supports abiraterone/olaparib as first-line option in mCRPC
I disagree with the headline but looks like this is the link that is postable. Final overall survival data for PROpel – (abi + olaparib in first line mCRPC). Not fully mature, trend towards improvement, greatest in patients with BRCA mutated disease with almost no difference in the patients with non BRCA mutated disease.